Considering the increasing amount of data about the pathophysiology of COVID-19 and the key role of coagulation and microcirculation alterations [35,36,37], this could be a good rationale to support the beneficial effect of an IgM and IgA enriched immunoglobulin G therapy. Here, CD79A is linked to COVID-19.